This article has Open Peer Review reports available.
Intraprostatic injection of botulinum toxin type- A relieves bladder outlet obstruction in human and induces prostate apoptosis in dogs
© Chuang et al; licensee BioMed Central Ltd. 2006
Received: 06 December 2005
Accepted: 18 April 2006
Published: 18 April 2006
With the increasing interest with botulinum toxin – A (BTX-A) application in the lower urinary tract, we investigated the BTX-A effects on the canine prostate and also in men with bladder outlet obstruction (BOO) due to benign prostatic hyperplasia (BPH).
Transperineal injection into the prostate using transrectal ultrasound (TRUS) was performed throughout the study. Saline with or without 100 U of BTX-A was injected into mongrel dogs prostate. One or 3 months later, the prostate was harvested for morphologic and apoptotic study. In addition, eight BPH patients refractory to α-blockers were treated with ultrasound guided intraprostatic injection of 200 U of BTX-A.
In the BTX-A treated dogs, atrophy and diffuse apoptosis was observed with H&E stain and TUNEL stain at 1 and 3 months. Clinically, the mean prostate volume, symptom score, and quality of life index were significantly reduced by 18.8%, 73.1%, and 61.5% respectively. Maximal flow rate significantly increased by 72.0%.
Intraprostatic BTX-A injection induces prostate apotosis in dogs and relieves BOO in humans. It is therefore a promising alternative treatment for refractory BOO due to BPH.
Benign prostatic hyperplasia (BPH) is a common feature of the aging male and is regarded as a major cause of bladder outlet obstruction (BOO), which results in obstructive and irritative voiding symptoms. The bothersome urinary symptoms decrease the quality of life of these patients . Transurethral resection of prostate (TURP) has been considered as a gold standard for the treatment of symptomatic BPH. However, there have been concerns about the safety of TURP, with long-term morbidity including retrograde ejaculation, bladder neck contracture, and impotence [2–4]. Thus, there has been much interest in the development of alternative treatments. However, one feature of any of the minimally invasive techniques in clinical use to date is that they are permanent. Some men are simply not ready or willing to undergo an irreversible procedure in order to treat their symptomatic BPH.
Botulinum toxin A (BTX-A) has been shown to block the release of neurotransmitters such as acetylcholine at the neuromuscular junction as well as in autonomic neurons [5–7]. BTX-A has been successfully used to treat various conditions including blepharospasm, strabismus, focal dystonias, and achalasia . Injection of BTX-A into the urethra or bladder is an effective treatment for various types of lower urinary tract dysfunction for 6 months or longer [7–9]. Furthermore, previous studies in the rats have shown that intraurethral injection of BTX-A has significant inhibitory effects on urethral norepinephrine release  and intraprostatic injection of BTX-A induces selective denervation and subsequent atrophy of the glands . Recent clinical studies have shown promising results after injection of BTX-A into lateral lobes of prostate for relieving voiding dysfunction due to BPH [12–14]. However, the histological change of prostatic tissue and mechanisms after BTX-A injection was not clear. The dog is one of a few animals that can develop BPH spontaneously and is frequently used as an animal model for human prostatic hyperplasia [15, 16]. Therefore, the present study investigated morphologic and apoptotic change in the canine prostate after BTX-A injection. We also reported 8 cases of symptomatic BPH patients treated with BTX-A.
One or three months after BTX-A or normal saline injection (N = 2, in each group), the prostate was harvested for histological examination. The prostatic tissues were embedded in paraffin blocks after formalin fixation. Consecutive sections were taken for morphologic examination with hematoxylin and eosin stain and for study of apoptosis with TUNEL stain (terminal deoxynucleotidyl-mediated deoxyuridine triphosphate nick end labeling stain)  using a commercially available kit (Detection Kit POD, Boehringer Mannhein, Mannhein, Germany). Apoptotic nuclei were identified by detected fluorescence.
Patient profiles and results after botulinum toxin-A treatment.
Prostate volume (ml) Pre/Post
PSA (ng/ml) Pre/Post
QOL index Pre/Post
Peak Flow (ml/s) Pre/Post
Residual urine (ml) Pre/Post
All men were evaluated pre and postoperatively for International Prostate Symptom Score (IPSS, 0–35, mild 0–7, moderate 8–18, severe ≥ 19), quality of life indices (QOL, 0–6, indicating increasing severity of symptoms and low quality of life) , peak urinary flow rates, post-void residual volume detected by ultrasound, and prostate volume by TRUS (0.52 × Length × Height × Width). Results were evaluated one month after the procedure. Quantitative data are expressed throughout this paper as means plus or minus standard error. Statistical analyses were performed using Student's t test for paired data with p < 0.05 considered significant.
The TUNEL staining of sections of control animals (1 and 3 month groups) revealed only a small amount of apoptosis (Fig. 4B). The TUNEL stained sections of tissue of BTX-A treated animals revealed fluorescence in the nuclei throughout the evaluated tissue, but fluorescence was predominantly seen in the nuclei of the glands (Fig. 4D). This significant glandular apoptosis was seen at both 1 and 3 month after intraprostatic BTX-A injection.
The proportion of TUNEL positive nuclei per 500 nuclei was quantified at ×400 magnification using a 10 × 10 grid in the eyepiece in 4 fields. The mean apoptotic cells in the BTX-A treated group and control group were 187.5 ± 20.4 and 6.5 ± 2.1, respectively (p < 0.05).
The follow-up period ranged from 3 to 8 months, mean 4.8 ± 0.6 months. No stress incontinence, retrograde ejaculation, erectile dysfunction, or systemic side effects were observed. Most patients reported improvement starting from 3 to 7 days post BTX-A treatment, reaching maximal effect in about 1 month, and maintaining effects as long as eight months.
At one month follow-up, the prostate volume, mean symptom score and quality of life index were significantly reduced by 18.8% (from 61.6 ± 8.7 to 50.0 ± 5.9 ml, p < 0.05), 73.1% (from 19.0 ± 1.8 to 5.1 ± 2.0, p < 0.05) and 61.5% (from 3.9 ± 0.3 to 1.5 ± 0.2, p < 0.05) respectively. The maximal flow rate was increased by 72.0% (from 7.5 ± 1.8 to 12.9 ± 0.5 ml/sec, p < 0.05). The residual urine was decreased by 86.2% (from 177.6 ± 71.7 to 24.5 ± 4.5 ml, p = 0.064). At three month follow-up, the effects were maintained and the prostate volume, mean symptom score, quality of life index, maximal flow rate, and residual urine were 49.5 ± 5.9 ml, 4.0 ± 0.9, 1.6 ± 0.3, 13.0 ± 0.5 ml/sec, and 22.1 ± 3.0 ml, respectively.
Although the etiology of BPH remains unknown, it has been suggested that BPH has two components: a static component that is related to prostatic enlargement and a dynamic component that reflects contraction of smooth muscle within the gland [1, 12]. The static component is under parasympathetic control and regulated by androgen, while the stromal smooth muscle is sympathetically influenced [20, 21]. Thus, drugs that relax smooth muscle within the prostate, such as α-adrenergic receptor blockers, and drugs that shrink the volume, such as 5 α reductase inhibitors, are used for the treatment of BPH.
Recent evidence suggests that BPH could be originated from neural dysregulation of the prostate and alterations in local neuropeptides . The prostatic neuroendocrine peptides may regulate the synthesis of prostatic secretory product, growth, and function [20, 21]. Thus, BTX-A which has a cholinergic receptor predilection in its action on nerve terminals as well as inhibition of release of noradrenalin might regulate the neural control of prostate and relieve the symptoms of benign prostatic obstruction.
There are some differences between the canine and human prostate, nevertheless, experimental findings on the canine prostate can be regarded as valuable information. Previous studies have used the canine mode to elucidate the effects of orchiectomy and androgen on the prostate [15, 22]. In the canine model, we used BTX-A 100 U for prostate injection, which dose might be about 2 times of the dose used in human (100 U for 15 kg in canine/200 U for 60 kg in human). However, the component of human prostate is different from the canine prostate. Species differences might have different responses to BTX-A treatment , therefore, the selected dose of BTX-A 100 U for the canine model cannot be completely interpreted to the human dose. Our present results suggest that injection of BTX-A into the canine prostate induced marked atrophy and diffuse apoptosis of prostate glands. The effect persisted for at least 3 months without any notable side effects. Doggweiler suggested that denervation can alter growth-factor expression in the prostate and resulted in programmed cell death . Kyprianou demonstrated that the suppression of sympathetic tone on the prostate induced prostate apoptosis . Expression of specific prostate apoptosis related genes, such as bcl2 and transforming growth factor-β has been implicated in the pathogenesis of BPH . Thus, apoptotic changes in the prostate after BTX-A treatment are likely to be related with reduced neurotrophic influence on the gland. Therefore, the induction of apoptosis may emerge as an attractive target for the management of BPH. As BPH might arise from neural dysregulation, BTX-A could potentially affect these neural mechanisms. Further study with staining of various neuropeptide markers in the dog prostate is undergoing for future report.
Although one of our patients did not reveal volume shrinkage, all of the 8 patients had improved in maximal flow rate, residual urine, IPSS score and quality of life indices, and had no side effects after BTX-A injection. The pathological features of BPH are heterogenous and include varying abnormalities of epithelium, smooth muscle and fibrous stroma. The relative proportion of epithelium and stroma is from 1:2 to 1:5 . It is possible that the predominant component of the BPH nodule may determines the response to specific therapy, for example, smooth muscle predominant nodules would respond to α-blockers and epithelial nodules to androgen-deprivation therapy [1, 24]. The possibility of BTX-A effects on the dynamic component of BPH might explain the patient without volume shrinkage, but improved in lower urinary symptoms. Taken together, BTX-A might reduce the benign prostatic obstruction no matter what the detrusor contractility is.
The effects of denervation provided by the BTX-A will wear off, as new axons re-sprout in approximately 6 months . Phelan et al reported that BTX-A effects on sphincter injection have prolonged subjective clinical efficacy beyond 6 months . The beneficial results of the present study were evident within 1 month, and they continued throughout the follow-up period. The duration of BTX-A effects might depend on the different characteristic of targeted tissue, therapeutic dose, and intervals. Patients will determine if and when subsequent injections are necessary. Since the application of BTX-A on the treatment of lower urinary dysfunction is currently off-level use in Taiwan, it was necessary to be approved by the institutional review board for the human use and animal study. In support of evidence based medicine practices, caution should be applied until larger randomized clinical studies are completed that will guide physicians in making decisions about the use of botulinum toxin in the prostate.
In conclusion, our preliminary results suggest that BTX-A induces prostate atrophy and apoptosis in the canine and improves lower urinary tract symptoms in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Intraprostate BTX-A injection may be a promising, reversible and alternative treatment for refractory BPH.
- Walsh PC: Treatment of benign prostatic hyperplasia. N Engl J Med. 1996, 335: 557-563.Google Scholar
- Roos NP, Wennberg JE, Malenka DJ, Fisher ES, McPherson K, Andersen TF, Cohen MM, Ramsey E: Mortality and reoperation after open and transurethral resection of the prostate for benign prostatic hyperplasia. N Engl J Med. 1989, 320: 1120-1124.View ArticlePubMedGoogle Scholar
- Bruskewitz RC, Larsen EH, Madsen P, Dorflinger T: 3-year follow-up of urinary symptoms after transurethral of the prostate. J Urol. 1986, 136: 613-615.PubMedGoogle Scholar
- Roehrborn C, McConnell J, Barry M, Benaim E, Bruskewitz R, Blute M: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol. 2003, 170: 530-547. 10.1097/01.ju.0000078083.38675.79.View ArticleGoogle Scholar
- Jankovic J, Brin MF: Therapeutic uses of botulinum toxin. N Engl J Med. 1991, 324: 1186-1194.View ArticlePubMedGoogle Scholar
- MacKenzie I, Burnstock G, Dolly JO: The effects of purified botulinum neurotoxin type A on cholinergic, adrenergic and non-adrenergic, atropine-resistant autonomi neuromuscular transmission. Neuroscience. 1982, 7: 997-1006. 10.1016/0306-4522(82)90056-2.View ArticlePubMedGoogle Scholar
- Smith CP, Chancellor MB: Emerging Role of botulinum toxin in the treatment of voiding dysfunction. J Urol. 2004, 171: 2128-2137. 10.1097/01.ju.0000127725.48479.89.View ArticlePubMedGoogle Scholar
- Phelan MW, Franks M, Somogyi GT, Yokoyama T, Fraser MO, Lavelle JP, Yoshimura N, Chancellor MB: Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol. 2001, 165: 1107-1110. 10.1097/00005392-200104000-00011.View ArticlePubMedGoogle Scholar
- Kuo HC: Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003, 61: 550-554. 10.1016/S0090-4295(02)02541-4.View ArticlePubMedGoogle Scholar
- Smith CP, Franks MF, McNeil BK, Ghosh R, deGroat WC, Chancellor MB, Somogyi GT: Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract. J Urol. 2003, 169: 1896-1900. 10.1097/01.ju.0000049202.56189.54.View ArticlePubMedGoogle Scholar
- Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA: Botox induced prostatic involution. Prostate. 1998, 37: 44-50. 10.1002/(SICI)1097-0045(19980915)37:1<44::AID-PROS7>3.0.CO;2-8.View ArticlePubMedGoogle Scholar
- Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A: Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003, 62: 259-265. 10.1016/S0090-4295(03)00477-1.View ArticlePubMedGoogle Scholar
- Chuang YC, Chiang PH, Huang CC, Yoshimura N, Chancellor MB: Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology. 2005, 66: 775-779. 10.1016/j.urology.2005.04.029.View ArticlePubMedGoogle Scholar
- Kuo HC: Prostate Botulinum toxin A injection- an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology. 2005, 65: 670-674. 10.1016/j.urology.2004.10.077.View ArticlePubMedGoogle Scholar
- Lin ATL, Chen MT, Chiang H, Yang CH, Chang LS: Effect of orchiectomy on the alpha adrenergic contractile response of dog prostate. J Urol. 1995, 154: 1930-1933. 10.1016/S0022-5347(01)66828-9.View ArticlePubMedGoogle Scholar
- Levy DA, Cromeens DM, Evans R, Stephens LC, von Eschenbach AC, Pisters LL: Transrectal ultrasound-guided intraprostatic injection of absolute ethanol with and without carmustine: a feasibility study in the canine model. Urology. 1999, 53: 1245-1251. 10.1016/S0090-4295(99)00043-6.View ArticlePubMedGoogle Scholar
- Chiang P-H, Chuang Y-C, Huang C-C, Chiang C-P: Pilot study of transperineal injection of dehydrated ethanol in the treatment of prostatic obstruction. Urology. 2003, 61: 797-801. 10.1016/S0090-4295(02)02514-1.View ArticlePubMedGoogle Scholar
- Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992, 119: 493-501. 10.1083/jcb.119.3.493.View ArticlePubMedGoogle Scholar
- Cockett A, Aso Y, Denis L: Prostate symptom score and quality of life assessment. Proceedings of the 2nd International Consultation on Benign Prostatic Hyperplasia (BPH) Paris. Edited by: Cockett ATK, Khoury S, Aso Y, et al. 1994, Jersey, Channel Island, Scientific Communication International, 553-555. June 27–30, 1993Google Scholar
- Lepor H, Baumann M, Shapiro E: Identification and characterization of alpha 1 adrenergic receptors in the canine prostate using [125I]-Heat. J Urol. 1987, 138: 1336-1339.PubMedGoogle Scholar
- Lau WA, Pennefather JN, Mitchelson FJ: Cholinergic facilitation of neurotransmission to the smooth muscle of the guinea-pig prostate gland. British J Pharmacology. 2000, 130: 1013-1020. 10.1038/sj.bjp.0703409.View ArticleGoogle Scholar
- Niu YJ, Ma TX, Zhang J, Xu Y, Han RF, Sun G: Androgen and prostatic stroma. Asian J Androl. 2003, 5: 19-26.PubMedGoogle Scholar
- Chuang YC, Huang CC, Kang HY, Chiang PH, de Miguel F, Yoshimura N, Chancellor MB: Novel action of Botulinum toxin on the stromal and epithelial components of prostate gland. J Urol. 2006, 173: 1158-1163. 10.1016/S0022-5347(05)00318-6.View ArticleGoogle Scholar
- Kyprianou N: Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol. 2003, 169: 1520-1525. 10.1097/01.ju.0000033280.29453.72.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2490/6/12/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.